ASSOCIATION NONALCOHOLIC FATTY LIVER DISEASE AND RISK OF HYPERTENSION : A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.53555/nnmhs.v9i6.1734Keywords:
Fatty liver, Non-alcoholic, Hypertension, Risk factors, Quality assessmentAbstract
Background: Nonalcoholic fatty liver disease (NAFLD) is a common liver disease characterized by fat accumulation in liver cells. It is linked to obesity and insulin resistance. NAFLD increases the risk of cardiovascular complications and liver-related problems, while its association with hypertension is not yet clear. Aim: to investigate the potential link between NAFLD and hypertension
Methods: This qualitative systematic review conducted a comprehensive search on Ovid-MEDLINE up until March 2021 to identify longitudinal observational studies examining the relationship between nonalcoholic fatty liver disease and the development of hypertension, following the guidelines of PRISMA. The study selection included longitudinal studies with a minimum one-year follow-up.
Results: Out of the initial 1108 articles, a final analysis of 11 observational cohort studies was conducted after excluding studies based on predetermined criteria, resulting in a total sample size of 390,348 individuals with an average follow-up period of 5.7 years. These studies, conducted in various regions, examined the relationship between NAFLD and incident hypertension using consistent diagnostic methods.
Conclusion: NAFLD is linked to a higher risk of hypertension, emphasizing the importance of monitoring and further investigating the impact of NAFLD severity on hypertension.
References
1. Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2(11):901–10.
2. Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World. Clin Liver Dis. 2016;20(2):205–14.
3. Huang T, Behary J, Zekry A. Non-alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management. Intern Med J. 2020;50(9):1038–47.
4. Wree A, Broderick L, Canbay A, Hoffman HM, Feldstein AE. From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol [Internet]. 2013;10(11):627–36. Available from: http://dx.doi.org/10.1038/nrgastro.2013.149
5. Brunt EM, Wong VWS, Nobili V, Day CP, Sookoian S, Maher JJ, et al. Nonalcoholic fatty liver disease. Nat Rev Dis Prim. 2015;1(December):1–22.
6. Zhao YC, Zhao GJ, Chen Z, She ZG, Cai J, Li H. Nonalcoholic Fatty Liver Disease: An Emerging Driver of Hypertension. Hypertension. 2020;275–84.
7. Bonnet F, Gastaldelli A, Pihan-Le Bars F, Natali A, Roussel R, Petrie J, et al. Gamma-glutamyltransferase, fatty liver index and hepatic insulin resistance are associated with incident hypertension in two longitudinal studies. J Hypertens. 2017;35(3):493–500.
8. Fan JG, Li F, Cai XB, Peng Y De, Ao QH, Gao Y. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J Gastroenterol Hepatol. 2007;22(7):1086–91.
9. Huh JH, Ahn SV, Koh SB, Choi E, Kim JY, Sung KC, et al. A prospective study of fatty liver index and incident hypertension: The KoGES-ARIRANG study. PLoS One. 2015;10(11):1–13.
10. Kim SS, Cho HJ, Kim HJ, Kang DR, Berry JR, Kim JH, et al. Nonalcoholic fatty liver disease as a sentinel marker for the development of diabetes mellitus in non-obese subjects. Dig Liver Dis [Internet]. 2018;50(4):370–7. Available from: http://dx.doi.org/10.1016/j.dld.2017.12.018
11. Lau K, Lorbeer R, Haring R, Schmidt CO, Wallaschofski H, Nauck M, et al. The association between fatty liver disease and blood pressure in a population-based prospective longitudinal study. J Hypertens. 2010;28(9):1829–35.
12. Liu P, Tang Y, Guo X, Zhu X, He M, Yuan J, et al. Bidirectional association between nonalcoholic fatty liver disease and hypertension from the Dongfeng-Tongji cohort study. J Am Soc Hypertens [Internet]. 2018;12(9):660–70. Available from: https://doi.org/10.1016/j.jash.2018.06.013
13. Ma J, Hwang SJ, Pedley A, Massaro JM, Hoffmann U, Chung RT, et al. Bi-directional analysis between fatty liver and cardiovascular disease risk factors. J Hepatol [Internet]. 2017;66(2):390–7. Available from: http://dx.doi.org/10.1016/j.jhep.2016.09.022
14. Roh JH, Park JH, Lee H, Yoon YH, Kim M, Kim YG, et al. A close relationship between nonalcoholic fatty liver disease marker and new-onset hypertension in healthy Korean adults. Korean Circ J. 2020;50(8):E76.
15. Ryoo JH, Suh YJ, Shin HC, Cho YK, Choi JM, Park SK. Clinical association between non-alcoholic fatty liver disease and the development of hypertension. J Gastroenterol Hepatol. 2014;29(11):1926–31.
16. Sung KC, Wild SH, Byrne CD. Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension. J Hepatol [Internet]. 2014;60(5):1040–5. Available from: http://dx.doi.org/10.1016/j.jhep.2014.01.009
17. Zhou K, Cen J. TI. 2018;1–7.
18. Ruhl CE, Everhart JE. Elevated Serum Alanine Aminotransferase and ?-Glutamyltransferase and Mortality in the United States Population. Gastroenterology [Internet]. 2009;136(2):477-485.e11. Available from: http://dx.doi.org/10.1053/j.gastro.2008.10.052
19. Ampuero J, Aller R, Gallego-Durán R, Crespo J, Calleja JL, García-Monzón C, et al. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH. J Hepatol [Internet]. 2020;73(1):17–25. Available from: https://doi.org/10.1016/j.jhep.2020.02.028
20. Artunc F, Schleicher E, Weigert C, Fritsche A, Stefan N, Häring HU. The impact of insulin resistance on the kidney and vasculature. Nat Rev Nephrol [Internet]. 2016;12(12):721–37. Available from: http://dx.doi.org/10.1038/nrneph.2016.145
21. Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology. 2009;49(3):1017–44.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Journal of Advance Research in Medical & Health Science (ISSN: 2208-2425)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
